Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
复制标题
DOI：
10.1158/0008-5472.can-07-3096
复制
发表时间：
2008-01-01
期刊：
影响因子：
11.2
通讯作者：
Jones, Richard J.
中科院分区：
文献类型：
--
作者：
Matsui, William;Wang, Qiuju;Jones, Richard J.
许多药物对多发性骨髓瘤有效，但大多数患者会复发。这种临床模式表明大多数癌细胞被消除，但具有介导肿瘤再生的克隆形成潜力的细胞相对具有化学抗性。我们之前的数据表明，CD138(+)多发性骨髓瘤浆细胞不能长期增殖，而是由克隆性CD138(neg) B细胞产生。我们比较了这些不同细胞类型对临床抗骨髓瘤药物的相对敏感性，发现地塞米松、来那地洛胺、硼替佐米和4-羟基环磷酰胺在体外抑制CD138(+)多发性骨髓瘤浆细胞，但对CD138(neg)前体细胞几乎没有影响。我们使用 Hoechst 侧群和 Aldeflor 测定进一步表征了克隆性多发性骨髓瘤细胞和染色细胞系。每次测定均鉴定出 CD138(neg) 细胞，表明它们具有高药物流出能力和细胞内药物解毒活性。我们还发现，表达记忆 B 细胞标记 CD20 和 CD27 的多发性骨髓瘤细胞可以在体外引起克隆性多发性骨髓瘤生长，并在初次和二次移植期间植入免疫缺陷非肥胖糖尿病/严重联合免疫缺陷小鼠。此外，侧群和 Aldeflor 检测都能够识别多发性骨髓瘤患者外周血中的循环克隆型记忆 B 细胞群。我们的结果表明，循环克隆型 B 细胞群代表多发性骨髓瘤干细胞，这些细胞的相对耐药性是由保护正常干细胞免受毒性损伤的过程介导的。
Many agents are active in multiple myeloma, but the majority of patients relapse. This clinical pattern suggests most cancer cells are eliminated, but cells with the clonogenic potential to mediate tumor regrowth are relatively chemoresistant. Our previous data suggested that CD138(+) multiple myeloma plasma cells cannot undergo long-term proliferation but rather arise from clonogenic CD138(neg) B cells. We compared the relative sensitivity of these distinct cell types to clinical antimyeloma agents and found that dexamethasone, lenadilomide, bortezomib, and 4-hydroxycyclophosphamide inhibited CD138(+) multiple myeloma plasma cells but had little effect on CD138(neg) precursors in vitro. We further characterized clonogenic multiple myeloma cells and stained cell lines using the Hoechst side population and Aldefluor assays. Each assay identified CD138(neg) cells suggesting that they possess high drug efflux capacity and intracellular drug detoxification activity. We also found that multiple myeloma cells expressing the memory B-cell markers CD20 and CD27 could give rise to clonogenic multiple myeloma growth in vitro and engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary and secondary transplantation. Furthermore, both the side population and Aldefluor assays were capable of identifying circulating clonotypic memory B-cell populations within the peripheral blood of multiple myeloma patients. Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury.